TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: MEDIHONEY® Gel Versus Collagenase for Wound Debridement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A signed and dated informed consent has been obtained from the subject.~* Subject is able and willing to comply with study procedures.~* Subject is able to comply with weekly visits.~* Subject is 18 years of age or older.~* There is presence of at least 50% or greater necrotic tissue (including slough and eschar) in the wound bed and a total wound surface area of \> 1cm2 to \< 64cm2.~* Subject will not have currently used parenteral or oral antibiotics except for UTI.~* Diabetic subjects: HbA1c \< 12.0 % within 90 days preceding enrollment.~* Pre-albumin greater than 16 mg/dl within 90 days preceding enrollment.~* Subject with a pressure ulcer must be currently receiving adequate pressure redistribution to the affected area via group 2 or 3 specialty bed, a static wheel chair cushion while patient is out of bed.~* Subject with diabetic plantar surface ulcer will use an offloading boot if ambulatory.~* Subject with a venous ulcer must be currently receiving and using compression therapy that can be managed daily.~* Subject and caregiver are trainable and able to perform dressing changes.~* Subject has no allergies to collagenase or honey.~* Subject has no allergies to semi-occlusive or absorptive secondary dressing.~* If subject has multiple wounds only the wound that fits the inclusion criteria will be selected. If more than one wound meets criteria then the largest wound will be selected.~Exclusion Criteria:~* Steroid use \>5mg daily.~* Subject is unable to cooperate with offloading and/or compression recommendations.~* ABI = or \>0.8 if the wound is located on a lower extremity.~* Wound has the presence of callus requiring sharp or surgical debridement within 3 days prior to randomization and/or needs debridement using any method other than the study agent throughout study treatment.~* Subject has medical instability as deemed by the investigator.~* Subject is pregnant.~* Subject has participated in another clinical trial or wound dressing evaluation in the 30 days prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Collagenase (Type: ACTIVE_COMPARATOR): This is an enzymatic debridement agent to remove non-viable tissue from wounds to be applied daily
- Active leptospermum honey (Type: ACTIVE_COMPARATOR): This is an active medicinal grade honey used to promote autolytic debridement and applied daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane and Percutaneous Coronary Intervention by Stent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Both gender.~2. Patients with coronary artery disease candidates for coronary angioplasty stent.~3. Cardiac catheterization on an urgent basis.~4. Coronary angioplasty in elective and urgency.~5. Age less than 80 years.~Exclusion Criteria:~1. Patients aged greater than or equal of 80 years.~2. Angioplasty balloon catheter statement.~3. Myocardial infarction with ST-segment elevation.~4. Angioplasty in saphenous vein grafts in patients after surgical revascularization.~5. Patient pregnant.~6. Dialytic insufficiency renal.~7. Patients submited a urgent cardiac catheterization but not progress with coronary angioplasty stent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane Group (Type: EXPERIMENTAL): Sevoflurane Group called group A patients will receive sevoflurane. The patients of group A will receive facial mask properly attached to your face, inspiratory fraction of sevoflurane 3%, with therapeutic target of 1.2% expired fraction into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. This procedure is sufficient to induce the pre anesthetic conditioning in the group exposed to sevoflurane. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
- Control Group (Type: PLACEBO_COMPARATOR): Control Group called group B patients who will not receive sevoflurane. The patient of group B will receive facial mask properly attached to your face into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with uncomplicated malaria will be enrolled in cohort 1~* Pediatric patients with uncomplicated malaria will be enrolled in cohort 2~* Pediatric patients with severe malaria will be enrolled in cohort 3~* Plasmodium falciparum malaria confirmed in blood smear~* Fever within the last 24 hours.~Exclusion Criteria:~* Treatment with an antimalarial agent within 72h of screening~* Severe concomitant disease~* Pregnant or breast-feeding women~* Women of child bearing potential not protected by an effective method of birth control~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Adult patients with uncomplicated malaria
- Cohort 2 (Type: EXPERIMENTAL): Pediatric patients with uncomplicated malaria
- Cohort 3 (Type: EXPERIMENTAL): Pediatric patients with severe malaria

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed advanced or metastatic adenocarcinoma of the stomach~* ECOG performance scale ≤ 2~* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)~* Adequate hepatic, renal, heart, and hematologic functions:~  * platelets\>80 × 109/L~ * neutrophil\>2.0 × 109/L~ * serum creatinine ≤ 1.5mg/dl~ * total bilirubin within upper limit of normal(ULN)~ * serum transaminase ≤ 2.5 × the ULN~Exclusion Criteria:~* Pregnant or lactating women~* Concurrent cancer~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix~* Neuropathy, brain, or leptomeningeal involvement~* Uncontrolled significant comorbid conditions and previous radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): administer sorafenib 400mg bid until disease progression or intolerable toxicity or patients withdrawal of consent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Compuflo Instrument for Thoracic ES Identification

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 80 years inclusive~* BMI 18.5 to 40 inclusive~* Scheduled for thoracic epidural anesthesia~Exclusion Criteria:~* Patients younger than 18 years or older than 80 years of age~* Patients with BMI less than 18.5 or greater than 40~* Contraindication to thoracic epidural anesthesia~* Allergy or hypersensitivity to local anesthetics~* Patients with preexisting nerve damage~* Patients unable to provide written informed consent~* Individuals of vulnerable populations: children, pregnant women, prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Phase A - Thoracic ES with LOR (Type: EXPERIMENTAL): Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until loss of resistance (LOR) is perceived to identify the thoracic epidural space (ES). The Compuflo Epidural Instrument will be used to record pressure readings. The thoracic epidural procedure will then continue per standard of care.
- Phase B - Thoracic ES with Compuflo (Type: EXPERIMENTAL): Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until the Compuflo Epidural Instrument indicates that pressure has decreased. The loss of resistance technique will then be used to identify the thoracic epidural space. The thoracic epidural procedure will then continue per standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women with histologically confirmed breast cancer (by core needle biopsy)~* Women with \>= 2 cm clinically or radiologically measureable breast cancer~* Women scheduled to receive neoadjuvant chemotherapy as part of their treatment plan~* Women competent to sign study specific written Informed Consent~* Women willing to comply with protocol requirements~Exclusion Criteria:~* Women who are pregnant~* Women who have undergone open surgical (excisional) biopsy for breast cancer diagnosis~* Women who have had a prior history of breast cancer in the same breast~* Women with known cardiac shunt, pulmonary hypertension or hypersensitivity to perflutren agent~* Women who cannot consent for themselves

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (CEUS, SWE) (Type: EXPERIMENTAL): Patients undergo dynamic contrast-enhanced ultrasound imaging and shear wave elastography at baseline, 2-3 weeks after initiation of chemotherapy, and before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females of all races between 18 to 80 years of age.~* Diagnosed with primary autonomic failure and supine hypertension. Supine hypertension will be defined as systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 90 mmHg while lying down.~* Able and willing to provide informed consent.~Exclusion Criteria:~* Pregnancy or breast feeding.~* Hemoglobin \< 10.5 or hematocrit \< 32.~* High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, renal failure, history of stroke or myocardial infarction).~* Inability to give or withdraw informed consent.~* Other factors which in the investigator's opinion would prevent the patient from completing the protocol (e.g. clinically significant abnormalities on clinical, mental examination, or laboratory testing or inability to comply with the protocol).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Angiotensin-(1-7) (Type: EXPERIMENTAL): Patients will receive an intravenous infusion of five ascending doses of Angiotensin-(1-7). The doses are: 1, 2, 4, 8 and 16 ng/kg/min. Each dose will be maintained for 10 minutes, for a total of 50 minutes.
- Saline (Type: PLACEBO_COMPARATOR): Patients will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will be maintained for 50 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-65 years, male or female~* Elective liver transplantation~* United Network for Organ Sharing (UNOS) Level 2A/B or 3~* Serum albumin ≥ 30 g/L~* Comprehend all the procedures of this study~* Willing and able to give informed consent~Exclusion Criteria:~* Uncontrolled exo-hepatic malignant carcinomas~* Uncontrollable infections (including HIV infection)~* Need support of artificial liver or kidney, ventilator-dependant, coma or unstable hemodynamically~* Patients with a history of hypersensitivity to hydroxyethyl starch or albumin~* Urinary output less than 500 ml within 24 hours after operation~* Patients with intracranial bleeding~* Patients with other colloids for treating hypovolemia~* Patients with pulmonary edema~* Pregnant women or females of childbearing potential and lactating mothers~* Patients who are participating in other drug studies or who receive other investigational drugs within 30 days prior to the present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Local Anesthesia Versus Continuous Femoral Nerve Bloc After Total Knee Arthroplasty: Impact on Mean Discharge Aptitude Delay

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Total knee arthroplasty~* Age \> 18 years with social security covering.~* Written informed consent~Exclusion Criteria:~* Age \< 18 years~* ASA Physical Status \> III~* Body weight \< 50 kg~* Latex or silver allergy.~* Loco-regional anesthesia contraindication~* Chronic anticoagulant, corticoid or pain treatment.~* Rivaroxaban or enoxaparin contraindication~* Communication issues~* Patient under guardianship~* Pregnant or breast-feeding patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous femoral nerve bloc (Type: ACTIVE_COMPARATOR): Continuous femoral nerve bloc
- Continuous local anesthesia (Type: EXPERIMENTAL): Continuous local infiltration of local anesthetic in the operated knee.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histological confirmation of primary myelofibrosis or post essential thrombocythemic or polycythemic vera myelofibrosis~  * Reticulin fibrosis ≥ grade 1~* Evaluable and symptomatic disease worthy of treatment, characterized by ≥ 1 of the following:~  * Anemia, defined as hemoglobin \< 11 g/dL or erythrocyte transfusion dependence~ * Palpable and symptomatic splenomegaly (palpable and symptomatic hepatomegaly is acceptable if previously splenectomized)~ * Severe, disease-related constitutional symptoms, including ≥ 1 of the following:~    * Severe night sweats~   * Fevers~   * Weight loss~   * Bone pain~* Absence of t(9;22) by fluorescent in situ hybridization (FISH) or standard cytogenetics OR prior demonstration of a lack of this translocation~PATIENT CHARACTERISTICS:~* Eastern Co-operative Oncology Group (ECOG) performance status 0-3~* Absolute neutrophil count (ANC) ≥ 1,000/mm³~* Platelet count ≥ 50,000/mm³~* Creatinine ≤ 2.0 mg/dL~* Direct or total bilirubin ≤ 2.0 mg/dL~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times upper limit of normal (ULN) (≤ 5 times ULN if elevation is attributed to hepatic extramedullary hematopoiesis)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Not incarcerated in a municipality, county, state, or federal prison~* No serious medical condition or psychiatric illness that would preclude signing the informed consent~* No condition that, in the opinion of the treating physician, places the patient at unacceptable risk for study participation or confounds the ability to interpret study data~* Able to adhere to the study visit schedule and other study requirements~PRIOR CONCURRENT THERAPY:~* No other concurrent chemotherapy (e.g., hydroxyurea, thalidomide, interferon alpha, anagrelide, or other myelosuppressive agent) or experimental therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Hidradenitis Suppurativa made at the Montefiore Hidradenitis Suppurativa Treatment Center, with Hurley Stage 2-3 (defined as recurrent abscesses or boils with diffuse or broad involvement, multiple interconnected sinus tracts in the whole area)~* Failed maximal medical therapy for Hidradenitis Suppurativa or ineligible for standard medical therapy or surgery~* Age \> 20 years~* Women of childbearing age: must have a negative pregnancy test within 72 hours prior to the start of study therapy and agree to an adequate method of contraception throughout treatment and for at least 4 weeks after study contraception.~Exclusion Criteria:~* Pregnant women~* Individuals \< 20 years old

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose Radiotherapy (Type: EXPERIMENTAL): Patients will receive skin-directed radiotherapy, using a total prescription dose of 7.5 gy in five fractions of 1.5 gy over one week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histological proven non-small cell or small cell lung cancer UICC stage I-III (in case of small cell lung cancer: limited stage)~* WHO performance status 0-2~* Less than 10 % weight loss the last 6 months~* In case of previous chemotherapy, concurrent chemo-radiotherapy can start after a minimum of 21 days after the last chemotherapy course~* No recent (\< 3 months) severe cardiac disease (arrhythmia, congestive heart failure, infarction)~* No active peptic oesophagitis~* Life expectancy more than 6 months~* Measurable cancer~* Willing and able to comply with the study prescriptions~* 18 years or older~* Not pregnant and willing to take adequate contraceptive measures during the study~* Have given written informed consent before patient registration~* No previous radiotherapy to the chest~Exclusion Criteria:~* Not non-small cell or small cell histology, e.g. mesothelioma, lymphoma~* Malignant pleural or pericardial effusion~* History of prior chest radiotherapy~* Recent (\< 3 months) myocardial infarction~* Uncontrolled infectious disease~* Distant metastases (stage IV)~* Patients with active peptic oesophagitis in the last year~* Less than 18 years old~* Pregnant or not willing to take adequate contraceptive measures during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues